183 related articles for article (PubMed ID: 28685208)
1. Iron modulates the activity of monoamine oxidase B in SH-SY5Y cells.
Lu H; Chen J; Huang H; Zhou M; Zhu Q; Yao SQ; Chai Z; Hu Y
Biometals; 2017 Aug; 30(4):599-607. PubMed ID: 28685208
[TBL] [Abstract][Full Text] [Related]
2. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
Klegeris A; McGeer PL
Exp Neurol; 2000 Dec; 166(2):458-64. PubMed ID: 11085911
[TBL] [Abstract][Full Text] [Related]
3. Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions.
Hermida-Ameijeiras A; Méndez-Alvarez E; Sánchez-Iglesias S; Sanmartín-Suárez C; Soto-Otero R
Neurochem Int; 2004 Jul; 45(1):103-16. PubMed ID: 15082228
[TBL] [Abstract][Full Text] [Related]
4. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
[TBL] [Abstract][Full Text] [Related]
5. Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells.
Yi H; Akao Y; Maruyama W; Chen K; Shih J; Naoi M
J Neurochem; 2006 Jan; 96(2):541-9. PubMed ID: 16336631
[TBL] [Abstract][Full Text] [Related]
6. A link between monoamine oxidase-A and apoptosis in serum deprived human SH-SY5Y neuroblastoma cells.
Fitzgerald JC; Ufer C; Billett EE
J Neural Transm (Vienna); 2007; 114(6):807-10. PubMed ID: 17393061
[TBL] [Abstract][Full Text] [Related]
7. Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
Naoi M; Maruyama W; Shamoto-Nagai M
J Neural Transm (Vienna); 2018 Nov; 125(11):1635-1650. PubMed ID: 29279995
[TBL] [Abstract][Full Text] [Related]
8. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection.
Naoi M; Maruyama W; Akao Y; Yi H; Yamaoka Y
J Neural Transm Suppl; 2006; (71):67-77. PubMed ID: 17447417
[TBL] [Abstract][Full Text] [Related]
9. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase B activatable red fluorescence probe for bioimaging in cells and zebrafish.
Yang Z; Zhong T; Mo Q; He J; Chong J; Hu X; Zhao S; Qin J
Bioorg Chem; 2024 Apr; 145():107156. PubMed ID: 38387393
[TBL] [Abstract][Full Text] [Related]
11. Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells.
Fitzgerald JC; Ufer C; De Girolamo LA; Kuhn H; Billett EE
J Neurochem; 2007 Dec; 103(6):2189-99. PubMed ID: 17883400
[TBL] [Abstract][Full Text] [Related]
12. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
13. A Strategy for Specific Fluorescence Imaging of Monoamine Oxidase A in Living Cells.
Wu X; Shi W; Li X; Ma H
Angew Chem Int Ed Engl; 2017 Nov; 56(48):15319-15323. PubMed ID: 29027345
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
[TBL] [Abstract][Full Text] [Related]
15. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
16. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
Naoi M; Riederer P; Maruyama W
J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
[TBL] [Abstract][Full Text] [Related]
17. 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.
Chung JY; Lee JW; Ryu CH; Min HK; Yoon YJ; Lim MJ; Park CH
J Neurosci Res; 2015 Aug; 93(8):1267-78. PubMed ID: 25711470
[TBL] [Abstract][Full Text] [Related]
18. The intracellular monoamine oxidase-A inhibitory activity and the protective effect of small hairtail-related peptides in nerve cells (SH-SY5Y).
Zhang A; Yang X; Su K; Xie J; Zhang X
Biosci Biotechnol Biochem; 2024 Feb; 88(3):322-332. PubMed ID: 38066695
[TBL] [Abstract][Full Text] [Related]
19. Subnanomolar indazole-5-carboxamide inhibitors of monoamine oxidase B (MAO-B) continued: indications of iron binding, experimental evidence for optimised solubility and brain penetration.
Tzvetkov NT; Antonov L
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):960-967. PubMed ID: 28726524
[TBL] [Abstract][Full Text] [Related]
20. Catecholamine degradation by monoamine oxidase in locus coeruleus neurons of the rat. An immunohistochemical study.
Kishimoto Y; Geffard M; Arai R
Brain Res; 2000 Mar; 859(2):373-7. PubMed ID: 10719089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
